RevvityRVTY
RVTY
About: Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
Employees: 11,500
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
154% more call options, than puts
Call options by funds: $7.52M | Put options by funds: $2.96M
95% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 43
60% more funds holding in top 10
Funds holding in top 10: 5 [Q2] → 8 (+3) [Q3]
17% more capital invested
Capital invested by funds: $11.8B [Q2] → $13.8B (+$1.99B) [Q3]
16% more repeat investments, than reductions
Existing positions increased: 183 | Existing positions reduced: 158
8% more funds holding
Funds holding: 478 [Q2] → 514 (+36) [Q3]
3.35% less ownership
Funds ownership: 91.34% [Q2] → 87.99% (-3.35%) [Q3]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$135
14%
upside
Avg. target
$141
19%
upside
High target
$146
23%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
B of A Securities Derik De Bruin 68% 1-year accuracy 13 / 19 met price target | 17%upside $138 | Buy Upgraded | 13 Dec 2024 |
Barclays Luke Sergott 23% 1-year accuracy 11 / 48 met price target | 14%upside $135 | Overweight Maintained | 25 Nov 2024 |
TD Cowen Dan Brennan 41% 1-year accuracy 12 / 29 met price target | 22%upside $144 | Buy Maintained | 5 Nov 2024 |
Bernstein Eve Burstein 57% 1-year accuracy 4 / 7 met price target | 22%upside $145 | Outperform Maintained | 5 Nov 2024 |
Raymond James Andrew Cooper 25% 1-year accuracy 3 / 12 met price target | 23%upside $146 | Outperform Maintained | 5 Nov 2024 |
Financial journalist opinion
Based on 5 articles about RVTY published over the past 30 days
Positive
Zacks Investment Research
1 week ago
RVTY Stock Falls Despite FDA Nod for Automated Testosterone Test
Revvity aims to expand the FDA-cleared menu for the EUROIMMUN family of ChLIA automation solutions to serve a wider patient pool.
Neutral
Business Wire
1 week ago
Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing
WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, co-developed with Element Biosciences, Inc., a life science company democratizing access to advanced DNA and multi-omic sequencing solutions. This initiative builds upon Revvity's recent introduction of an automated next-generation sequencing (NGS) workflow for newborn sequencing research and stren.
Neutral
Business Wire
1 week ago
Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its fourth quarter and full year 2024 financial results prior to market open on Friday, January 31, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available via this reg.
Neutral
Business Wire
1 week ago
Revvity Announces FDA Clearance for First Automated Free Testosterone Test
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN's automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. This innovative test is the first of its kind to receive FDA clearance for direct quantitative measurement of free testosterone levels, marking a significant advancement in diagnostic capabilities for androgen disorders. Key features of the.
Positive
Zacks Investment Research
2 weeks ago
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
RVTY's strong product portfolio raises optimism about the stock.
Neutral
Business Wire
1 month ago
Revvity to Present at J.P. Morgan Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the 43rd annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 8:15 a.m. PT in San Francisco, CA. President and Chief Executive Officer Prahlad Singh will provide an update on the Company and its strategic priorities. To access the presentation, a live audio webcast will be available via this page. A replay of the presentation will be posted on the Revvity Investor Relations website after the event and.
Positive
Seeking Alpha
1 month ago
Safe Biopharma: Revvity's Recurring Revenues And Diagnostics
Revvity, Inc. is a leader in life sciences and diagnostics with diversified revenue streams and a strong balance sheet, making it a low-risk biopharma play. The company's recurring revenue base (80%) from consumables, services, and software ensures predictable income and financial stability. The company has a global footprint and an estimated TAM exceeding $60 billion, showcasing its significant market opportunity.
Positive
Benzinga
1 month ago
Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst
BofA Securities reports that the Life Sciences Tools sector struggled in fiscal year 2024.
Negative
Zacks Investment Research
1 month ago
Why Is Revvity (RVTY) Down 8.7% Since Last Earnings Report?
Revvity (RVTY) reported earnings 30 days ago. What's next for the stock?
Neutral
Business Wire
2 months ago
Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced an expansion of its work with Genomics England that leverages both organizations' expertise and resources to advance critical genomic initiatives across the United Kingdom. Building on the parties' long and productive work history, this advanced collaboration is dedicated to accelerating Genomics England's renowned research programs, supporting diverse areas in genomics, and fostering talent in innovative healthcare fi.
Charts implemented using Lightweight Charts™